Encoding Clinical Data with the Human Phenotype Ontology for Computational Differential Diagnostics. (24th July 2019)

• Record Type: Journal Article
• Authors: Köhler, Sebastian; Øien, N. Christine; Buske, Orion J.; Groza, Tudor; Jacobsen, Julius O. B.; McNamara, Craig; Vasilevsky, Nicole; Carmody, Leigh C.; Gourdine, J. P.; Gargano, Michael; McMurry, Julie A.; Danis, Daniel; Mungall, Christopher J.; Smedley, Damian; Haendel, Melissa; Robinson, Peter N.
• Editors: Dracopoli, Nicholas C.; Haines, Jonathan L.; Korf, Bruce R.; Morton, Cynthia C.; Seidman, Christine E.; Seidman, J.G.; Smith, Douglas R.
• Is Part Of: Current protocols in human genetics. Volume 103(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-07-24
• Subjects: differential diagnosis -- exome -- Human Phenotype Ontology -- HPO -- phenotype; Human genetics -- Laboratory manuals; Genetic Techniques; Human genetics; Laboratory manuals; 599.935028
• DOI: 10.1002/cphg.92
• Languages: English
• ISSNs: 1934-8258

Abstract

Abstract: The Human Phenotype Ontology (HPO) is a standardized set of phenotypic terms that are organized in a hierarchical fashion. It is a widely used resource for capturing human disease phenotypes for computational analysis to support differential diagnostics. The HPO is frequently used to create a set of terms that accurately describe the observed clinical abnormalities of an individual being evaluated for suspected rare genetic disease. This profile is compared with computational disease profiles in the HPO database with the aim of identifying genetic diseases with comparable phenotypic profiles. The computational analysis can be coupled with the analysis of whole‐exome or whole‐genome sequencing data through applications such as Exomiser. This article explains how to choose an optimal set of HPO terms for these cases and enter them with software, such as PhenoTips and PatientArchive, and demonstrates how to use Phenomizer and Exomiser to generate a computational differential diagnosis. © 2019 by John Wiley & Sons, Inc.